2:25-cv-14606
Jazz Pharma Ireland Ltd v. Granules India Ltd
I. Executive Summary and Procedural Information
- Parties & Counsel:
- Plaintiff: Jazz Pharmaceuticals Ireland Limited (Ireland)
- Defendant: Granules India Limited (India)
- Plaintiff's Counsel: Saul Ewing LLP
- Case Identification: 2:25-cv-14606, D.N.J., 08/13/2025
- Venue Allegations: Plaintiff alleges venue is proper in the District of New Jersey based on Defendant's purposeful business conduct in the district, the registration of its fully owned subsidiary Granules USA, Inc. in New Jersey, and the district being a likely destination for the accused product.
- Core Dispute: Plaintiff alleges that Defendant's filing of an Abbreviated New Drug Application (ANDA) for a generic version of Plaintiff's Xywav® oral solution constitutes an act of infringement of fourteen U.S. patents.
- Technical Context: The technology relates to pharmaceutical compositions of gamma-hydroxybutyrate (GHB), also known as oxybate, used for treating sleep disorders such as narcolepsy, with a focus on mixed-salt formulations and methods of administration.
- Key Procedural History: This action arises under the Hatch-Waxman Act following Defendant's submission of ANDA No. 220725 and its corresponding Paragraph IV Certification, which alleges that Plaintiff's patents are invalid and/or will not be infringed. The complaint certifies that this matter is related to Jazz Pharma Ireland Ltd v. Lupin Inc, et al., No. 21-14271 (D.N.J.), as it involves the same plaintiff and patents.
Case Timeline
| Date | Event |
|---|---|
| 2012-01-11 | U.S. Patent No. 8,591,922 Priority Date |
| 2012-12-14 | U.S. Patent No. 8,901,173 Priority Date; U.S. Patent No. 9,132,107 Priority Date; U.S. Patent No. 10,195,168 Priority Date; U.S. Patent No. 10,675,258 Priority Date; U.S. Patent No. 11,426,373 Priority Date; U.S. Patent No. 11,554,102 Priority Date |
| 2013-03-01 | U.S. Patent No. 8,772,306 Priority Date; U.S. Patent No. 9,050,302 Priority Date; U.S. Patent No. 9,486,426 Priority Date; U.S. Patent No. 10,213,400 Priority Date; U.S. Patent No. 10,864,181 Priority Date; U.S. Patent No. 11,253,494 Priority Date; U.S. Patent No. 11,986,446 Priority Date |
| 2013-11-26 | U.S. Patent No. 8,591,922 Issued |
| 2014-07-08 | U.S. Patent No. 8,772,306 Issued |
| 2014-12-02 | U.S. Patent No. 8,901,173 Issued |
| 2015-06-09 | U.S. Patent No. 9,050,302 Issued |
| 2015-09-15 | U.S. Patent No. 9,132,107 Issued |
| 2016-11-08 | U.S. Patent No. 9,486,426 Issued |
| 2019-02-05 | U.S. Patent No. 10,195,168 Issued |
| 2019-02-26 | U.S. Patent No. 10,213,400 Issued |
| 2020-06-09 | U.S. Patent No. 10,675,258 Issued |
| 2020-12-15 | U.S. Patent No. 10,864,181 Issued |
| 2022-02-22 | U.S. Patent No. 11,253,494 Issued |
| 2022-08-30 | U.S. Patent No. 11,426,373 Issued |
| 2023-01-17 | U.S. Patent No. 11,554,102 Issued |
| 2024-05-21 | U.S. Patent No. 11,986,446 Issued |
| 2025-07-02 | Granules sends Paragraph IV Notice Letter (earliest date) |
| 2025-08-13 | Complaint Filed |
II. Technology and Patent(s)-in-Suit Analysis
U.S. Patent No. 8,591,922 - "Gamma-hydroxybutyrate compositions and their use for the treatment of disorders"
- Patent Identification: U.S. Patent No. 8,591,922, "Gamma-hydroxybutyrate compositions and their use for the treatment of disorders," issued November 26, 2013 (the "'922 Patent") (Compl. ¶3).
The Invention Explained
- Problem Addressed: The patent addresses the high sodium content of existing gamma-hydroxybutyrate (GHB) drug products, such as Xyrem®, which can be undesirable for patients with conditions like hypertension, heart disease, or renal disease, or who are at risk of stroke ('922 Patent, col. 1:49-2:6).
- The Patented Solution: The invention is a pharmaceutical composition that reduces the overall sodium load by using a mixture of different salts of GHB. Specifically, it combines sodium GHB with potassium, magnesium, and calcium salts of GHB, aiming to provide a safer alternative while maintaining therapeutic efficacy and acceptable pharmaceutical properties ('922 Patent, abstract; '922 Patent, col. 2:31-45).
- Technical Importance: This mixed-salt approach allows for the treatment of narcolepsy and other disorders in a broader patient population, including those for whom high sodium intake is a significant health concern ('922 Patent, col. 2:35-42).
Key Claims at a Glance
The complaint does not identify specific asserted claims. A representative independent claim, Claim 1, recites:
- A pharmaceutical composition of gamma-hydroxybutyrate (GHB) comprising a mixture of salts of GHB,
- wherein the mixture consists of a sodium salt of gamma-hydroxybutyrate (Na.GHB), a potassium salt of gamma-hydroxybutyrate (K.GHB), a magnesium salt of gamma-hydroxybutyrate (Mg.(GHB)2), and a calcium salt of gamma-hydroxybutyrate (Ca.(GHB)2),
- wherein the Na.GHB, K.GHB, Mg.(GHB)2, and Ca.(GHB)2 salts are present in a wt/wt % ratio of about 8%:23%:21%:48%, respectively.
U.S. Patent No. 8,772,306 - "Method of administration of gamma hydroxybutyrate with monocarboxylate transporters"
- Patent Identification: U.S. Patent No. 8,772,306, "Method of administration of gamma hydroxybutyrate with monocarboxylate transporters," issued July 8, 2014 (the "'306 Patent") (Compl. ¶4).
The Invention Explained
- Problem Addressed: The therapeutic effect of GHB can be altered by the co-administration of other drugs that inhibit monocarboxylate transporters (MCTs), which are involved in GHB's movement in the body. This creates potential safety and efficacy issues for patients taking multiple medications ('306 Patent, col. 1:21-30).
- The Patented Solution: The patent describes a method for safely administering GHB by adjusting its dosage to compensate for drug-drug interactions with MCT inhibitors. For example, the dose of GHB is reduced when taken with valproate (which increases GHB's effect) and increased when taken with diclofenac (which decreases GHB's effect) ('306 Patent, abstract; '306 Patent, col. 1:31-2:16).
- Technical Importance: This method provides a systematic way to manage known drug-drug interactions involving GHB, enhancing patient safety in polypharmacy settings.
Key Claims at a Glance
The complaint does not identify specific asserted claims. A representative independent claim, Claim 1, recites:
- A method for reducing adverse effects caused by a combination of gamma-hydroxybutyrate (GHB) or a salt thereof and divalproex sodium in a patient comprising:
- administering a reduced daily dosage amount of GHB or a salt thereof to the patient of between about 15% to about 30%,
- compared to a daily dosage amount of GHB or salt thereof administered to the patient in the absence of concomitant administration of divalproex sodium;
- wherein the patient is concomitantly administered divalproex sodium.
U.S. Patent No. 8,901,173 - "Gamma-hydroxybutyrate compositions and their use for the treatment of disorders"
U.S. Patent No. 8,901,173, "Gamma-hydroxybutyrate compositions and their use for the treatment of disorders," issued December 2, 2014 (Compl. ¶5). This patent, similar to the '922 Patent, describes pharmaceutical compositions with mixed salts of GHB to reduce sodium content. It claims specific ratios of GHB salts, including mixtures of three salts, intended to provide therapeutic benefits while being suitable for patients with sodium-sensitive conditions. The complaint alleges Granules' proposed generic Xywav® product will infringe one or more claims (Compl. ¶¶55-57).
U.S. Patent No. 9,050,302 - "Method of administration of gamma hydroxybutyrate with monocarboxylate transporters"
U.S. Patent No. 9,050,302, "Method of administration of gamma hydroxybutyrate with monocarboxylate transporters," issued June 9, 2015 (Compl. ¶6). This patent, similar to the '306 Patent, describes methods for safely administering GHB by adjusting the dosage in response to concomitant administration of MCT inhibitors like valproate or diclofenac. It claims specific dosage adjustments to mitigate potential adverse effects from drug-drug interactions. The complaint alleges infringement by Granules' proposed generic product (Compl. ¶¶64-66).
U.S. Patent No. 9,132,107 - "Gamma-hydroxybutyrate compositions and their use for the treatment of disorders"
U.S. Patent No. 9,132,107, "Gamma-hydroxybutyrate compositions and their use for the treatment of disorders," issued September 15, 2015 (Compl. ¶7). This patent discloses pharmaceutical compositions containing mixed salts of GHB to create low-sodium alternatives to existing treatments. It claims specific formulations comprising various combinations of sodium, potassium, magnesium, and calcium oxybates designed for treating disorders like narcolepsy. The complaint alleges infringement by Granules' proposed generic product (Compl. ¶¶73-75).
U.S. Patent No. 9,486,426 - "Method of administration of gamma hydroxybutyrate with monocarboxylate transporters"
U.S. Patent No. 9,486,426, "Method of administration of gamma hydroxybutyrate with monocarboxylate transporters," issued November 8, 2016 (Compl. ¶8). This patent covers methods of administering GHB to a patient by adjusting the dose based on whether the patient is also taking an MCT inhibitor, such as valproate. The invention aims to ensure safety and efficacy by accounting for known drug-drug interactions. The complaint alleges infringement by Granules' proposed generic product (Compl. ¶¶82-84).
U.S. Patent No. 10,195,168 - "Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders"
U.S. Patent No. 10,195,168, "Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders," issued February 5, 2019 (Compl. ¶9). This patent claims pharmaceutical compositions comprising mixed salts of GHB, including sodium, potassium, magnesium, and calcium, in specific ratios. The invention is directed at providing a low-sodium GHB formulation for treating sleep disorders. The complaint alleges infringement by Granules' proposed generic product (Compl. ¶¶91-93).
U.S. Patent No. 10,213,400 - "Method of administration of gamma hydroxybutyrate with monocarboxylate transporters"
U.S. Patent No. 10,213,400, "Method of administration of gamma hydroxybutyrate with monocarboxylate transporters," issued February 26, 2019 (Compl. ¶10). This patent relates to methods of safely administering GHB by adjusting dosage when co-administered with MCT inhibitors like valproate or diclofenac. The claims focus on specific dosing regimens to manage drug-drug interactions and maintain patient safety. The complaint alleges infringement by Granules' proposed generic product (Compl. ¶¶100-102).
U.S. Patent No. 10,675,258 - "Method of using gamma-hydroxybutyrate compositions for the treatment of disorders"
U.S. Patent No. 10,675,258, "Method of using gamma-hydroxybutyrate compositions for the treatment of disorders," issued June 9, 2020 (Compl. ¶11). This patent describes methods of treating narcolepsy by administering mixed-salt GHB compositions. The claims cover specific dosing regimens and formulations designed to be safer for patients with sodium-sensitive conditions. The complaint alleges infringement by Granules' proposed generic product (Compl. ¶¶109-111).
U.S. Patent No. 10,864,181 - "Method of administration of gamma hydroxybutyrate with monocarboxylate transporters"
U.S. Patent No. 10,864,181, "Method of administration of gamma hydroxybutyrate with monocarboxylate transporters," issued December 15, 2020 (Compl. ¶12). This patent covers methods of adjusting GHB dosage to account for interactions with MCT inhibitors. It claims specific methods of dose modification for patients also taking drugs like valproate to ensure therapeutic efficacy and safety. The complaint alleges infringement by Granules' proposed generic product (Compl. ¶¶118-120).
U.S. Patent No. 11,253,494 - "Method of administration of gamma hydroxybutyrate with monocarboxylate transporters"
U.S. Patent No. 11,253,494, "Method of administration of gamma hydroxybutyrate with monocarboxylate transporters," issued February 22, 2022 (Compl. ¶13). Continuing the theme of the '306 family, this patent claims methods for adjusting GHB dosage based on co-administration with MCT inhibitors. It provides further specific dosing instructions to manage drug interactions with substances like divalproex sodium. The complaint alleges infringement by Granules' proposed generic product (Compl. ¶¶127-129).
U.S. Patent No. 11,426,373 - "Gamma-hydroxybutyrate compositions and their use for the treatment of disorders"
U.S. Patent No. 11,426,373, "Gamma-hydroxybutyrate compositions and their use for the treatment of disorders," issued August 30, 2022 (Compl. ¶14). This patent claims pharmaceutical compositions of mixed GHB salts intended to have a reduced sodium content. The claims specify particular formulations and their use in treating sleep disorders, aiming to provide a safer alternative to high-sodium GHB products. The complaint alleges infringement by Granules' proposed generic product (Compl. ¶¶136-138).
U.S. Patent No. 11,554,102 - "Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders"
U.S. Patent No. 11,554,102, "Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders," issued January 17, 2023 (Compl. ¶15). This patent claims mixed-salt GHB compositions, focusing on specific ratios of cations (Na, K, Mg, Ca) to achieve a low-sodium formulation. The invention is intended for treating narcolepsy and other conditions responsive to GHB. The complaint alleges infringement by Granules' proposed generic product (Compl. ¶¶145-147).
U.S. Patent No. 11,986,446 - "Method of administration of gamma hydroxybutyrate with monocarboxylate transporters"
U.S. Patent No. 11,986,446, "Method of administration of gamma hydroxybutyrate with monocarboxylate transporters," issued May 21, 2024 (Compl. ¶16). This patent claims methods of administering GHB while accounting for drug interactions with MCT inhibitors like valproate. The claims focus on dose-adjustment protocols to ensure patient safety and efficacy. The complaint alleges infringement by Granules' proposed generic product (Compl. ¶¶154-156).
III. The Accused Instrumentality
Product Identification
The accused instrumentality is "Granules' Proposed Product," a generic version of Jazz Pharmaceuticals' Xywav® oral solution, for which Granules India Limited submitted ANDA No. 220725 to the FDA (Compl. ¶¶1, 32).
Functionality and Market Context
The complaint alleges that the accused product is a "calcium, magnesium, potassium, and sodium oxybates oral solution" (Compl. ¶17; Compl. ¶32). As a generic equivalent to Xywav®, it is intended for the same therapeutic uses, including the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy (Compl. ¶19). The filing of the ANDA signifies Granules' intent to manufacture, use, and sell this product in the United States prior to the expiration of the patents-in-suit (Compl. ¶¶1, 33). The complaint further alleges that the labeling for the branded product, Xywav®, instructs physicians and patients on administration methods that are claimed in the patents-in-suit, suggesting the generic product's label will do the same (Compl. ¶21).
No probative visual evidence provided in complaint.
IV. Analysis of Infringement Allegations
The complaint alleges that the submission of ANDA No. 220725 constitutes infringement of one or more claims of each of the patents-in-suit under 35 U.S.C. § 271(e)(2)(A) (Compl. ¶37; Compl. ¶46). The complaint does not provide specific claim charts or an element-by-element infringement analysis. The following tables summarize a potential infringement theory for representative claims based on the description of the accused product in the complaint.
U.S. Patent No. 8,591,922 Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A pharmaceutical composition of gamma-hydroxybutyrate (GHB) comprising a mixture of salts of GHB, wherein the mixture consists of a sodium salt..., a potassium salt..., a magnesium salt..., and a calcium salt of gamma-hydroxybutyrate... | Granules' Proposed Product is alleged to be a "calcium, magnesium, potassium, and sodium oxybates oral solution." | ¶17; ¶32 | col. 10:60-65 |
| wherein the Na.GHB, K.GHB, Mg.(GHB)2, and Ca.(GHB)2 salts are present in a wt/wt % ratio of about 8%:23%:21%:48%, respectively. | The complaint does not specify the exact formulation of Granules' Proposed Product, but as a generic of Xywav®, it is expected to have a composition that falls within the scope of the claimed ratios. | ¶17; ¶32 | col. 10:60-65 |
U.S. Patent No. 8,772,306 Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A method for reducing adverse effects caused by a combination of gamma-hydroxybutyrate (GHB) or a salt thereof and divalproex sodium in a patient comprising: | Plaintiff alleges that the labeling for the branded product, Xywav®, instructs users on administration methods covered by the patent claims, and that the generic label will do the same. | ¶20; ¶21 | col. 1:31-41 |
| administering a reduced daily dosage amount of GHB or a salt thereof to the patient of between about 15% to about 30%... wherein the patient is concomitantly administered divalproex sodium. | The complaint alleges the Xywav® label, which the accused product's label is expected to follow, instructs users "to modify the dose of Xywav® for patients receiving... oxybates when divalproex sodium (valproate) is concomitantly administered." | ¶20 | col. 1:31-41 |
- Identified Points of Contention:
- Scope Questions: For composition patents like the '922 Patent, a central question will be whether the specific formulation in Granules' ANDA falls within the claimed weight-percent ratios. The interpretation of the term "about" will be critical to determining the scope of these claims.
- Technical Questions: For method patents like the '306 Patent, a key issue will be induced infringement. The analysis will focus on whether Granules' proposed product labeling instructs or encourages medical professionals to adjust GHB dosage in a manner that performs the steps recited in the claims, particularly when co-administered with drugs like divalproex sodium (valproate).
V. Key Claim Terms for Construction
The Term: "about"
Context and Importance
This term appears in the composition claims of the '922 Patent (and related patents) in the context of specific weight-percent ratios (e.g., "about 8%:23%:21%:48%"). The construction of "about" will be central to determining whether Granules' formulation, which must be bioequivalent to Xywav®, literally infringes. Practitioners may focus on this term because it directly controls the boundary of the claimed chemical composition.
Intrinsic Evidence for Interpretation
- Evidence for a Broader Interpretation: The repeated use of "about" throughout the specification in describing various percentages and ranges may suggest the patentee did not intend for the numerical values to be precise and exact ('922 Patent, col. 2:46-6:14).
- Evidence for a Narrower Interpretation: The '922 Patent defines the term "approximately" as meaning "within 1, 2, 3, or 4 standard deviations" or within a specific percentage of a given value (e.g., 10% or 5%) ('922 Patent, col. 7:28-36). A defendant may argue this explicit definition limits the scope of "about" to a specific, calculable range, preventing it from covering formulations that deviate beyond that definition.
The Term: "reduced daily dosage amount"
Context and Importance
This term is central to method patents like the '306 Patent, which claim methods of adjusting GHB dosage. Claim 1 of the '306 Patent quantifies this as a reduction "of between about 15% to about 30%." The infringement analysis for inducement will depend on whether the instructions on Granules' proposed label lead to a dose reduction that falls within this construed range.
Intrinsic Evidence for Interpretation
- Evidence for a Broader Interpretation: The specification describes the invention as a general method to "diminish the additive effects" of co-administration with valproate, which could support an argument that any clinically meaningful reduction intended to achieve this purpose falls within the claim's scope ('306 Patent, col. 2:10-16).
- Evidence for a Narrower Interpretation: Claim 1 itself provides a specific numerical range ("about 15% to about 30%"). A party may argue that this explicit range should be strictly construed and that dosage adjustments falling outside this range, even if intended to mitigate side effects, do not infringe. The patent's summary of the invention also highlights this specific reduction percentage ('306 Patent, col. 1:31-41).
VI. Other Allegations
Indirect Infringement
The complaint pleads both induced and contributory infringement for all fourteen patents-in-suit (Compl. ¶¶40-41; Compl. ¶¶49-50). The inducement allegations are based on the assertion that Granules' proposed product, upon approval, will be marketed with a label that encourages and instructs physicians and patients to use the product in an infringing manner, such as for the treatment of narcolepsy or with specific dose modifications for drug interactions (Compl. ¶¶19-21). Contributory infringement is alleged on the basis that the proposed product is especially adapted for an infringing use and has no substantial non-infringing use (Compl. ¶41).
Willful Infringement
The complaint does not use the word "willful" but alleges for each patent that the case is "an exceptional one" and requests an award of attorneys' fees under 35 U.S.C. § 285 (Compl. ¶44). The factual basis for this allegation appears to be pre-suit knowledge, based on Granules' act of sending a Paragraph IV Certification notice letter to Jazz Pharmaceuticals, which asserted the patents-in-suit are invalid and/or not infringed (Compl. ¶35).
VII. Analyst's Conclusion: Key Questions for the Case
- A core issue will be one of definitional scope and bioequivalence: Can the term "about," as applied to the specific weight-percent ratios in the composition claims (e.g., '922 Patent), be construed to cover the formulation in Granules' ANDA? This will involve a technical comparison between the ANDA product, which must be bioequivalent to Xywav®, and the precise boundaries of the patent claims.
- A second central question will be one of induced infringement: Does the anticipated label for Granules' generic product contain instructions that direct or encourage healthcare providers to perform the patented methods of dose-adjustment claimed in patents like the '306 Patent, particularly for patients also taking drugs known to interact with GHB, such as divalproex?
- A broader question, raised by Defendant's Paragraph IV certification, will be the validity of the patent estate: The case will likely involve a significant challenge to the validity of numerous claims across the fourteen asserted patents, raising questions of obviousness in light of the state of the art for GHB formulations and treatment methods at the time of the inventions.